Survodutide

Survodutide is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 2 labelled variants: 5mg and 10mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, Survodutide sits alongside Retatrutide, Tesamorelin, and Ipamorelin. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, Survodutide is generally treated as a GLP-1R/GcgR dual agonist (BI 456906) with a C18 fatty diacid conjugate enabling extended albumin-bound half-life in pharmacokinetic models. Survodutide co-activates GLP-1R and GcgR with near-balanced potency — a different pharmacological profile from the GLP-1-biased mazdutide — resulting in more equivalent Gs-cAMP contributions from both receptor pathways in co-expression systems. Its C18 fatty diacid conjugate supports once-weekly pharmacokinetic modelling analogous to semaglutide, enabling half-life comparisons across fatty acid chain length and conjugation site in albumin-binding assays.

Balanced GLP-1R/GcgR agonism is mechanistically interesting because glucagon and GLP-1 produce near-opposite effects on hepatic glucose output in isolated hepatocyte models, yet co-activation of both receptors in vivo produces complex outcomes not predictable from single-receptor data alone. Survodutide provides a balanced-agonism reference to benchmark against GLP-1-biased analogs. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Survodutide behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare Survodutide with Retatrutide, Tesamorelin, and Ipamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.